MedTrace Logo

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)

NCT00616070 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2011-06-30

No results posted yet for this study

Summary

The purpose of this phase III study is to determine the safety and efficacy of difluprednate in the management of inflammation following ocular surgery.

Conditions

Interventions

DRUG

Difluprednate

Difluprednate

OTHER

Placebo

Vehicle

Sponsors & Collaborators

  • Sirion Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Roger Vogel, MD · Sirion Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00616070 on ClinicalTrials.gov